Cassava Sciences Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is far larger — about 2.4× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 104,717,733). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| FLNA | MSTZ | |
|---|---|---|
Market Cap | $39.40M | $94.46M |
Volume | 759,018 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $27.92 |
52-Week Low | $0.68 | $2.29 |
Typical Hold Time | 37 Days | 8 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.
Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →